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Background:
Dual antiplatelet therapy (DAPT) is commonly used post cardiac catheterization in
patients after percutaneous coronary intervention (PCI). If patients also need to be on
an anticoagulant, triple antithrombotic therapy increases risk for gastrointestinal
bleeding. This can increase hospitalization rates. At Banner University Medical Center
South (BUMCS), it had been recognized patients on dual or triple therapy post cardiac
catheterization had been readmitted due to gastrointestinal bleed. Gastro-protective
therapy had been linked to reduce gastrointestinal (GI) bleeding in high risk
patients. The purpose of the project was to determine how many patients, post
cardiac catheterization patients on dual/triple antithrombotic therapy, received
concomitant gastro-protective therapy per ACCF/ACG/AHA guidelines.1 Dual antiplatelet therapy is the standard of care for patients receiving percutaneouscoronary interventions and has been shown to vastly reduce the cardiac risks in this
patient population, however simultaneously increasing their risk for bleeding. In an
effort to reduce overall risk, it is important to identify methods that can reduce the risk
of adverse events in necessary drug regimens in these patients. The use of gastro-
protective medications can also help with better compliance of the antithrombotic
therapy as well as decrease the risk of recurrent cardiovascular events.2 In previous
studies, it has been shown the concomitant use of PPI/H2RA can reduce GI bleeding
in post catheterization patients. However, this project did not have the same results
and indicated that there was no significance of patients being on concomitant
PPI/H2RA.
Limitations:
Due to the narrow time frame of reviewing post-PCI readmissions only 30-days after
discharge, only one GI bleed was found. If the 30-day review was extended, more
bleeds might have been recorded. Extending chart reviews past 30-days, should be
conducted to determine if there is higher rates of bleeds and readmission rates. There
were other limitations that could be rectified to better analyze bleeds in patients on
antithrombotic therapy.
• It is unknown if patients were readmitted to hospitals outside of BUMCS (including
Banner University Medical Center Tucson) and thus, were not included.
• Alcohol/drug use and Over-the-Counter products (like NSAIDS) were self-reported.
• It was assumed that the participant’s electronic health records contained accurate
past medical history information.
• The DAPT Score should have been used to assess bleed risk for those on DAPT
therapy instead of the HAS-Bled Score.
CONCLUSION
• A retrospective analysis of 230 patients were reviewed and an analysis was
performed on a total of 148 patients who underwent cardiac catheterization. The
electronic health record of the 148 patients were reviewed during January 2016
through December 2016.
• A data collection form created by the investigators was used to extract the data from
patient charts. Patients discharged on dual/triple antithrombotic therapy were
identified and included for assessment. The presence of concomitant gastro-
protective therapy, antithrombotic regimen, demographics, risk factors, and 30-day
readmission status were also collected and analyzed.
• The two comparison groups were patients on dual/triple antithrombotic therapy with
concomitant PPI/H2RA therapy and patients on DAPT/triple antithrombotic therapy
with no concomitant PPI/H2RA therapy.
• Patient charts were reviewed and collected by one investigator and to ensure that
the data was collected correctly, another investigator reviewed the data collection.
• The statistical tests performed to compare the groups were independent t-test for
mean age and chi square for all other comparisons. The p-value was set at 0.05.
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• Patients that received dual antiplatelet therapy: 134
• Patients that received triple antithrombotic therapy: 12
• Patients that received neither treatment: 2
• There were no significant differences between those on gastro-protective therapy (n = 54, 36%) and those
not on gastro-protective therapy (n = 94, 64%) with concomitant dual/triple antithrombotic therapy (p =
0.241).
• A total of 30 readmissions, 30 days within stent placement, were found.
• Among admissions, one patient was attributed to gastrointestinal bleeding. The patient was on gastro-
protective therapy and readmitted 11 days after discharge.
RESULTS 
The purpose of this project was to compare the rate of readmissions, due to
gastrointestinal bleeding, among patients with and without gastro-protective therapy.
One patient was readmitted with the primary outcome, gastrointestinal bleeding,
within 30 days of cardiac catheterization. It was determined that concomitant gastro-
protective therapy with dual/triple antithrombotic therapy had no effect on the rate of
readmissions due to GI-bleeding 30 days post-cardiac catheterization at BUMCS.
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DATA
After completion of the project, BUMCS can implement a protocol to alert all
physicians for patients discharged with dual/triple antithrombotic therapy who may
need to be placed on a PPI/H2RA. The ultimate goal is to decrease readmission
rates, due to gastrointestinal bleeding in post-PCI patients and improve patient
outcomes.
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